mirror of
https://github.com/soapingtime/diyhrt.git
synced 2026-09-01 02:20:18 +02:00
[automated] update transfemscience
This commit is contained in:
github-actions
BIN
Binary file not shown.
BIN
Binary file not shown.
BIN
Binary file not shown.
File diff suppressed because one or more lines are too long
File diff suppressed because one or more lines are too long
File diff suppressed because one or more lines are too long
File diff suppressed because one or more lines are too long
@@ -1 +1 @@
|
||||
<?xml version="1.0" encoding="utf-8"?><feed xmlns="http://www.w3.org/2005/Atom" ><generator uri="https://jekyllrb.com/" version="3.9.5">Jekyll</generator><link href="https://transfemscience.org/feed-posts.xml" rel="self" type="application/atom+xml" /><link href="https://transfemscience.org/" rel="alternate" type="text/html" /><updated>2024-04-05T17:34:44-07:00</updated><id>https://transfemscience.org/feed-posts.xml</id><title type="html">Transfeminine Science</title><subtitle>Transfeminine Science is a site for information on hormone therapy for transfeminine people.</subtitle><author><name>Transfeminine Science</name></author></feed>
|
||||
<?xml version="1.0" encoding="utf-8"?><feed xmlns="http://www.w3.org/2005/Atom" ><generator uri="https://jekyllrb.com/" version="3.9.5">Jekyll</generator><link href="https://transfemscience.org/feed-posts.xml" rel="self" type="application/atom+xml" /><link href="https://transfemscience.org/" rel="alternate" type="text/html" /><updated>2024-04-11T21:03:56-07:00</updated><id>https://transfemscience.org/feed-posts.xml</id><title type="html">Transfeminine Science</title><subtitle>Transfeminine Science is a site for information on hormone therapy for transfeminine people.</subtitle><author><name>Transfeminine Science</name></author></feed>
|
||||
@@ -1,4 +1,4 @@
|
||||
<?xml version="1.0" encoding="utf-8"?><feed xmlns="http://www.w3.org/2005/Atom" ><generator uri="https://jekyllrb.com/" version="3.9.5">Jekyll</generator><link href="https://transfemscience.org/feed.xml" rel="self" type="application/atom+xml" /><link href="https://transfemscience.org/" rel="alternate" type="text/html" /><updated>2024-04-05T17:34:44-07:00</updated><id>https://transfemscience.org/feed.xml</id><title type="html">Transfeminine Science | Articles</title><subtitle>Transfeminine Science is a site for information on hormone therapy for transfeminine people.</subtitle><author><name>Transfeminine Science</name></author><entry><title type="html">Puberty Blockers: A Review of GnRH Analogues in Transgender Youth</title><link href="https://transfemscience.org/articles/puberty-blockers/" rel="alternate" type="text/html" title="Puberty Blockers: A Review of GnRH Analogues in Transgender Youth" /><published>2022-01-30T15:04:00-08:00</published><updated>2022-01-31T00:00:00-08:00</updated><id>https://transfemscience.org/articles/puberty-blockers</id><content type="html" xml:base="https://transfemscience.org/articles/puberty-blockers/"><![CDATA[<h1 id="puberty-blockers-a-review-of-gnrh-analogues-in-transgender-youth">Puberty Blockers: A Review of GnRH Analogues in Transgender Youth</h1>
|
||||
<?xml version="1.0" encoding="utf-8"?><feed xmlns="http://www.w3.org/2005/Atom" ><generator uri="https://jekyllrb.com/" version="3.9.5">Jekyll</generator><link href="https://transfemscience.org/feed.xml" rel="self" type="application/atom+xml" /><link href="https://transfemscience.org/" rel="alternate" type="text/html" /><updated>2024-04-11T21:03:56-07:00</updated><id>https://transfemscience.org/feed.xml</id><title type="html">Transfeminine Science | Articles</title><subtitle>Transfeminine Science is a site for information on hormone therapy for transfeminine people.</subtitle><author><name>Transfeminine Science</name></author><entry><title type="html">Puberty Blockers: A Review of GnRH Analogues in Transgender Youth</title><link href="https://transfemscience.org/articles/puberty-blockers/" rel="alternate" type="text/html" title="Puberty Blockers: A Review of GnRH Analogues in Transgender Youth" /><published>2022-01-30T15:04:00-08:00</published><updated>2022-01-31T00:00:00-08:00</updated><id>https://transfemscience.org/articles/puberty-blockers</id><content type="html" xml:base="https://transfemscience.org/articles/puberty-blockers/"><![CDATA[<h1 id="puberty-blockers-a-review-of-gnrh-analogues-in-transgender-youth">Puberty Blockers: A Review of GnRH Analogues in Transgender Youth</h1>
|
||||
|
||||
<!-- Supports up to four authors per article currently (author, author2, author3, author4) -->
|
||||
|
||||
@@ -4521,13 +4521,13 @@ Using the term desistence in this way does not imply anything about the identity
|
||||
<li>Quaynor, S. D., Stradtman, E. W., Kim, H., Shen, Y., Chorich, L. P., Schreihofer, D. A., & Layman, L. C. (2013). Delayed Puberty and Estrogen Resistance in a Woman with Estrogen Receptor α Variant. <em>New England Journal of Medicine</em>, <em>369</em>(2), 164–171. [DOI:<a href="https://doi.org/10.1056/nejmoa1303611">10.1056/nejmoa1303611</a>]</li>
|
||||
<li>Rinaldi, S., Geay, A., Déchaud, H., Biessy, C., Zeleniuch-Jacquotte, A., Akhmedkhanov, A., Shore, R. E., Riboli, E., Toniolo, P., & Kaaks, R. (2002). Validity of free testosterone and free estradiol determinations in serum samples from postmenopausal women by theoretical calculations. <em>Cancer Epidemiology and Prevention Biomarkers</em>, <em>11</em>(10), 1065–1071. [<a href="https://scholar.google.com/scholar?cluster=18409886331928026045">Google Scholar</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/12376508/">PubMed</a>] [<a href="https://aacrjournals.org/cebp/article/11/10/1065/166164/Validity-of-Free-Testosterone-and-Free-Estradiol">URL</a>]</li>
|
||||
<li>Vermeulen, A., Verdonck, L., & Kaufman, J. M. (1999). A critical evaluation of simple methods for the estimation of free testosterone in serum. <em>The Journal of Clinical Endocrinology & Metabolism</em>, <em>84</em>(10), 3666–3672. [DOI:<a href="https://doi.org/10.1210/jcem.84.10.6079">10.1210/jcem.84.10.6079</a>]</li>
|
||||
</ul>]]></content><author><name>{"first_name"=>"Aly", "last_name"=>"W.", "author-link"=>"/about/#aly", "articles-link"=>"/articles-by-author/aly/"}</name></author><category term="github" /><category term="workspace" /><summary type="html"><![CDATA[Supplement: The Interactions of Sex Hormones with Sex Hormone-Binding Globulin and Relevance for Transfeminine Hormone Therapy By Aly | First published July 8, 2020 | Last modified March 14, 2023]]></summary></entry><entry><title type="html">Bicalutamide and its Adoption by the Medical Community for Use in Transfeminine Hormone Therapy</title><link href="https://transfemscience.org/articles/bica-adoption/" rel="alternate" type="text/html" title="Bicalutamide and its Adoption by the Medical Community for Use in Transfeminine Hormone Therapy" /><published>2020-07-01T18:39:00-07:00</published><updated>2024-04-02T00:00:00-07:00</updated><id>https://transfemscience.org/articles/bica-adoption</id><content type="html" xml:base="https://transfemscience.org/articles/bica-adoption/"><![CDATA[<h1 id="bicalutamide-and-its-adoption-by-the-medical-community-for-use-in-transfeminine-hormone-therapy">Bicalutamide and its Adoption by the Medical Community for Use in Transfeminine Hormone Therapy</h1>
|
||||
</ul>]]></content><author><name>{"first_name"=>"Aly", "last_name"=>"W.", "author-link"=>"/about/#aly", "articles-link"=>"/articles-by-author/aly/"}</name></author><category term="github" /><category term="workspace" /><summary type="html"><![CDATA[Supplement: The Interactions of Sex Hormones with Sex Hormone-Binding Globulin and Relevance for Transfeminine Hormone Therapy By Aly | First published July 8, 2020 | Last modified March 14, 2023]]></summary></entry><entry><title type="html">Bicalutamide and its Adoption by the Medical Community for Use in Transfeminine Hormone Therapy</title><link href="https://transfemscience.org/articles/bica-adoption/" rel="alternate" type="text/html" title="Bicalutamide and its Adoption by the Medical Community for Use in Transfeminine Hormone Therapy" /><published>2020-07-01T18:39:00-07:00</published><updated>2024-04-06T00:00:00-07:00</updated><id>https://transfemscience.org/articles/bica-adoption</id><content type="html" xml:base="https://transfemscience.org/articles/bica-adoption/"><![CDATA[<h1 id="bicalutamide-and-its-adoption-by-the-medical-community-for-use-in-transfeminine-hormone-therapy">Bicalutamide and its Adoption by the Medical Community for Use in Transfeminine Hormone Therapy</h1>
|
||||
|
||||
<!-- Supports up to four authors per article currently (author, author2, author3, author4) -->
|
||||
|
||||
<p>By
|
||||
<!-- First author --><a href="/about/#aly">Aly</a><!-- Second author --><!-- Third author --><!-- Fourth author --> | First published July 1, 2020
|
||||
| Last modified April 2, 2024</p>
|
||||
| Last modified April 6, 2024</p>
|
||||
|
||||
<h2 id="abstract--tldr">Abstract / TL;DR</h2>
|
||||
|
||||
@@ -4667,8 +4667,8 @@ Using the term desistence in this way does not imply anything about the identity
|
||||
<li>Gómez-Aguilar, F., Martínez-Sánchez, L., Arias-Constantí, V., Muñoz-Santanach, D., & Sarquella-Brugada, G. (2023). QT prolongation and Torsade de Pointes in a 13-year-old transgender adolescent in treatment with bicalutamide and tacrolimus. <em>Clinical Toxicology</em>, <em>61</em>(Suppl 1 [<em>43rd International Congress of the European Association of Poisons Centres and Clinical Toxicologists (EAPCCT), 23–26 May 2023, Palma de Mallorca, Spain</em>]), 81–82 (abstract no. 170). [DOI:<a href="https://doi.org/10.1080/15563650.2023.2192024">10.1080/15563650.2023.2192024</a>] [<a href="https://www.eapcct.org/publicfile.php?folder=congress&file=Abstracts_Mallorca23.pdf#page=81">PDF</a>] [<a href="https://doi.org/10.1007/s40278-023-45800-4">Reactions Weekly</a>]</li>
|
||||
<li>Karakılıç Özturan, E., Öztürk, A. P., Baş, F., Erdoğdu, A. B., Kaptan, S., Kardelen Al, A. D., Poyrazoğlu, Ş., Yıldız, M., Direk, N., Yüksel, Ş., & Darendeliler, F. (2023). Endocrinological Approach to Adolescents with Gender Dysphoria: Experience of a Pediatric Endocrinology Department in a Tertiary Center in Turkey. <em>Journal of Clinical Research in Pediatric Endocrinology</em>, <em>15</em>(3), 276–284. [DOI:<a href="https://doi.org/10.4274/jcrpe.galenos.2023.2023-1-13">10.4274/jcrpe.galenos.2023.2023-1-13</a>]</li>
|
||||
<li>Vierregger, K., Tetzlaff, M., Zimmerman, B., Dunn, N., Finney, N., Lewis, K., Slomoff, R., & Strutner, S. (May 2023). Bicalutamide Use as Antiandrogen in Trans Feminine Adults - A Safety Profile. <em>National Transgender Health Summit (NTHS) 2023 Symposium</em>. [<a href="https://web.archive.org/web/20240321010915/https://d1keuthy5s86c8.cloudfront.net/static/ems/upload/files/nyhs_202305_agenda_pdf_lbjyz.pdf">Event Agenda PDF</a>] [<a href="https://whova.com/embedded/session/D7SYg0LqOnCqwqXqLsWNIdaSkH1LCYZ1IG6HZi0Pc-U%3D/3000743/">Symposium Session</a>] [<a href="https://prevention.ucsf.edu/transhealth/education/nths">Symposium Abstracts/Program Book</a>]</li>
|
||||
<li>Vierregger, K. S. (November 2023). Bicalutamide Use as Antiandrogen in Trans Feminine Adults - A Safety Profile. <em>USPATH Scientific Symposium, November 1-5, 2023, The Westin Westminster, Westminster, Colorado, Abstract Submissions</em>, 96–96 (abstract no. SAT-B2-T4). [<a href="https://www.wpath.org/media/cms/Upcoming%20Conferences/2023/Schedules/Final%20USPATH%202023%20Scientific%20Symposium%20Main%20Program%20-%20Full%20Schedule.pdf">Symposium Schedule</a>] [<a href="https://files.transfemscience.org/pdfs/Vierregger%20et%20al.%20(2023)%20-%20Bicalutamide%20Use%20as%20Antiandrogen%20in%20Trans%20Feminine%20Adults%20-%20A%20Safety%20Profile%20(USPATH%202023,%20abstract%20no.%20SAT-B2-T4).pdf">PDF</a>] [<a href="https://files.transfemscience.org/pdfs/wpath-symposia-materials/USPATH%202023%20Symposium%20Abstracts.pdf#page=96">Full Abstract Book</a>]</li>
|
||||
<li>Warus, J. (November 2023). Safety of Bicalutamide as Anti-Androgenic Therapy in Gender Affirming Care for Adolescents and Young Adults: A Retrospective Chart Review. <em>USPATH Scientific Symposium, November 1-5, 2023, The Westin Westminster, Westminster, Colorado, Abstract Submissions</em>, 124–124 (abstract no. SUN-B1-T5). [<a href="https://www.wpath.org/media/cms/Upcoming%20Conferences/2023/Schedules/Final%20USPATH%202023%20Scientific%20Symposium%20Main%20Program%20-%20Full%20Schedule.pdf">Symposium Schedule</a>] [<a href="https://files.transfemscience.org/pdfs/Warus%20et%20al.%20(2023)%20-%20Safety%20of%20Bicalutamide%20as%20Anti-Androgenic%20Therapy%20in%20Gender%20Affirming%20Care%20for%20Adolescents%20and%20Young%20Adults_%20A%20Retrospective%20Chart%20Review%20(USPATH%202023,%20abstract%20no.%20SUN-B1-T5).pdf">PDF</a>] [<a href="https://files.transfemscience.org/pdfs/wpath-symposia-materials/USPATH%202023%20Symposium%20Abstracts.pdf#page=124">Full Abstract Book</a>]</li>
|
||||
<li>Vierregger, K., Tetzlaf, M., Zimmerman, B., Dunn, N., Finney, N., Lewis, K., Slomoff, R., & Strutner, S. (November 2023). Bicalutamide Use as Antiandrogen in Trans Feminine Adults - A Safety Profile. <em>USPATH Scientific Symposium, November 1-5, 2023, The Westin Westminster, Westminster, Colorado, Abstract Submissions</em>, 96–96 (abstract no. SAT-B2-T4). [<a href="https://www.wpath.org/media/cms/Upcoming%20Conferences/2023/Schedules/Final%20USPATH%202023%20Scientific%20Symposium%20Main%20Program%20-%20Full%20Schedule.pdf">Symposium Schedule</a>] [<a href="https://files.transfemscience.org/pdfs/Vierregger%20et%20al.%20(2023)%20-%20Bicalutamide%20Use%20as%20Antiandrogen%20in%20Trans%20Feminine%20Adults%20-%20A%20Safety%20Profile%20(USPATH%202023,%20abstract%20no.%20SAT-B2-T4).pdf">PDF</a>] [<a href="https://files.transfemscience.org/pdfs/wpath-symposia-materials/USPATH%202023%20Symposium%20Abstracts.pdf#page=96">Full Abstract Book</a>]</li>
|
||||
<li>Warus, J., Rincon, M. G., Salvetti, B., & Olson-Kennedy, J. (November 2023). Safety of Bicalutamide as Anti-Androgenic Therapy in Gender Affirming Care for Adolescents and Young Adults: A Retrospective Chart Review. <em>USPATH Scientific Symposium, November 1-5, 2023, The Westin Westminster, Westminster, Colorado, Abstract Submissions</em>, 124–124 (abstract no. SUN-B1-T5). [<a href="https://www.wpath.org/media/cms/Upcoming%20Conferences/2023/Schedules/Final%20USPATH%202023%20Scientific%20Symposium%20Main%20Program%20-%20Full%20Schedule.pdf">Symposium Schedule</a>] [<a href="https://files.transfemscience.org/pdfs/Warus%20et%20al.%20(2023)%20-%20Safety%20of%20Bicalutamide%20as%20Anti-Androgenic%20Therapy%20in%20Gender%20Affirming%20Care%20for%20Adolescents%20and%20Young%20Adults_%20A%20Retrospective%20Chart%20Review%20(USPATH%202023,%20abstract%20no.%20SUN-B1-T5).pdf">PDF</a>] [<a href="https://files.transfemscience.org/pdfs/wpath-symposia-materials/USPATH%202023%20Symposium%20Abstracts.pdf#page=124">Full Abstract Book</a>]</li>
|
||||
<li>Wilde, B., Diamond, J. B., Laborda, T. J., Frank, L., O’Gorman, M. A., & Kocolas, I. (2023). Bicalutamide-Induced Hepatotoxicity in a Transgender Male-to-Female Adolescent. <em>Journal of Adolescent Health</em>, <em>74</em>(1), 202–204. [DOI:<a href="https://doi.org/10.1016/j.jadohealth.2023.08.024">10.1016/j.jadohealth.2023.08.024</a>]</li>
|
||||
<li>Burgener, K., DeBosch, B., Wang, J., Lewis, C., & Herrick, C. J. (2024). Bicalutamide does not raise transaminases in comparison to alternative anti-androgen regimens among transfeminine adolescents and young adults: a retrospective cohort study. <em>medRxiv</em>, preprint. [DOI:<a href="https://www.medrxiv.org/content/10.1101/2024.02.21.24302999v1">10.1101/2024.02.21.24302999v1</a>] [<a href="https://www.medrxiv.org/content/medrxiv/early/2024/02/23/2024.02.21.24302999.full.pdf">PDF</a>]</li>
|
||||
<li>Fuqua, J. S., Shi, E., & Eugster, E. A. (2024). A retrospective review of the use of bicalutamide in transfeminine youth; a single center experience. <em>International Journal of Transgender Health</em>, advance online publication. [DOI:<a href="https://doi.org/10.1080/26895269.2023.2294321">10.1080/26895269.2023.2294321</a>]</li>
|
||||
@@ -4770,7 +4770,7 @@ Using the term desistence in this way does not imply anything about the identity
|
||||
<li>Tomson, A., McLachlan, C., Wattrus, C., Adams, K., Addinall, R., Bothma, R., Jankelowitz, L., Kotze, E., Luvuno, Z., Madlala, N., Matyila, S., Padavatan, A., Pillay, M., Rakumakoe, M. D., Tomson-Myburgh, M., Venter, W., & de Vries, E. (2021). Southern African HIV Clinicians’ Society gender-affirming healthcare guideline for South Africa. <em>Southern African Journal of HIV Medicine</em>, <em>22</em>(1), a1299. [DOI:<a href="https://doi.org/10.4102/sajhivmed.v22i1.1299">10.4102/sajhivmed.v22i1.1299</a>] [<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8517808/pdf/HIVMED-22-1299.pdf">PDF</a>]</li>
|
||||
<li>van Kemenade, J. F., Cohen-Kettenis, P. T., Cohen, L., & Gooren, L. J. (1989). Effects of the pure antiandrogen RU 23.903 (anandron) on sexuality, aggression, and mood in male-to-female transsexuals. <em>Archives of Sexual Behavior</em>, <em>18</em>(3), 217–228. [DOI:<a href="https://doi.org/10.1007/BF01543196">10.1007/BF01543196</a>]</li>
|
||||
<li>Vierregger, K., Tetzlaff, M., Zimmerman, B., Dunn, N., Finney, N., Lewis, K., Slomoff, R., & Strutner, S. (2023). Bicalutamide Use as Antiandrogen in Trans Feminine Adults - A Safety Profile. <em>National Transgender Health Summit (NTHS) 2023 Symposium</em>. [<a href="https://web.archive.org/web/20240321010915/https://d1keuthy5s86c8.cloudfront.net/static/ems/upload/files/nyhs_202305_agenda_pdf_lbjyz.pdf">Event Agenda PDF</a>] [<a href="https://whova.com/embedded/session/D7SYg0LqOnCqwqXqLsWNIdaSkH1LCYZ1IG6HZi0Pc-U%3D/3000743/">Symposium Session</a>] [<a href="https://prevention.ucsf.edu/transhealth/education/nths">Symposium Abstracts/Program Book</a>]</li>
|
||||
<li>Vierregger, K. S. (2023). Bicalutamide Use as Antiandrogen in Trans Feminine Adults - A Safety Profile. <em>USPATH Scientific Symposium, November 1-5, 2023, The Westin Westminster, Westminster, Colorado, Abstract Submissions</em>, 96–96 (abstract no. SAT-B2-T4). [<a href="https://www.wpath.org/media/cms/Upcoming%20Conferences/2023/Schedules/Final%20USPATH%202023%20Scientific%20Symposium%20Main%20Program%20-%20Full%20Schedule.pdf">Symposium Schedule</a>] [<a href="https://files.transfemscience.org/pdfs/Vierregger%20et%20al.%20(2023)%20-%20Bicalutamide%20Use%20as%20Antiandrogen%20in%20Trans%20Feminine%20Adults%20-%20A%20Safety%20Profile%20(USPATH%202023,%20abstract%20no.%20SAT-B2-T4).pdf">PDF</a>] [<a href="https://files.transfemscience.org/pdfs/wpath-symposia-materials/USPATH%202023%20Symposium%20Abstracts.pdf#page=96">Full Abstract Book</a>]</li>
|
||||
<li>Warus, J. (2023). Safety of Bicalutamide as Anti-Androgenic Therapy in Gender Affirming Care for Adolescents and Young Adults: A Retrospective Chart Review. <em>USPATH Scientific Symposium, November 1-5, 2023, The Westin Westminster, Westminster, Colorado, Abstract Submissions</em>, 124–124 (abstract no. SUN-B1-T5). [<a href="https://www.wpath.org/media/cms/Upcoming%20Conferences/2023/Schedules/Final%20USPATH%202023%20Scientific%20Symposium%20Main%20Program%20-%20Full%20Schedule.pdf">Symposium Schedule</a>] [<a href="https://files.transfemscience.org/pdfs/Warus%20et%20al.%20(2023)%20-%20Safety%20of%20Bicalutamide%20as%20Anti-Androgenic%20Therapy%20in%20Gender%20Affirming%20Care%20for%20Adolescents%20and%20Young%20Adults_%20A%20Retrospective%20Chart%20Review%20(USPATH%202023,%20abstract%20no.%20SUN-B1-T5).pdf">PDF</a>] [<a href="https://files.transfemscience.org/pdfs/wpath-symposia-materials/USPATH%202023%20Symposium%20Abstracts.pdf#page=124">Full Abstract Book</a>]</li>
|
||||
<li>Vierregger, K., Tetzlaf, M., Zimmerman, B., Dunn, N., Finney, N., Lewis, K., Slomoff, R., & Strutner, S. (2023). Bicalutamide Use as Antiandrogen in Trans Feminine Adults - A Safety Profile. <em>USPATH Scientific Symposium, November 1-5, 2023, The Westin Westminster, Westminster, Colorado, Abstract Submissions</em>, 96–96 (abstract no. SAT-B2-T4). [<a href="https://www.wpath.org/media/cms/Upcoming%20Conferences/2023/Schedules/Final%20USPATH%202023%20Scientific%20Symposium%20Main%20Program%20-%20Full%20Schedule.pdf">Symposium Schedule</a>] [<a href="https://files.transfemscience.org/pdfs/Vierregger%20et%20al.%20(2023)%20-%20Bicalutamide%20Use%20as%20Antiandrogen%20in%20Trans%20Feminine%20Adults%20-%20A%20Safety%20Profile%20(USPATH%202023,%20abstract%20no.%20SAT-B2-T4).pdf">PDF</a>] [<a href="https://files.transfemscience.org/pdfs/wpath-symposia-materials/USPATH%202023%20Symposium%20Abstracts.pdf#page=96">Full Abstract Book</a>]</li>
|
||||
<li>Warus, J., Rincon, M. G., Salvetti, B., & Olson-Kennedy, J. (2023). Safety of Bicalutamide as Anti-Androgenic Therapy in Gender Affirming Care for Adolescents and Young Adults: A Retrospective Chart Review. <em>USPATH Scientific Symposium, November 1-5, 2023, The Westin Westminster, Westminster, Colorado, Abstract Submissions</em>, 124–124 (abstract no. SUN-B1-T5). [<a href="https://www.wpath.org/media/cms/Upcoming%20Conferences/2023/Schedules/Final%20USPATH%202023%20Scientific%20Symposium%20Main%20Program%20-%20Full%20Schedule.pdf">Symposium Schedule</a>] [<a href="https://files.transfemscience.org/pdfs/Warus%20et%20al.%20(2023)%20-%20Safety%20of%20Bicalutamide%20as%20Anti-Androgenic%20Therapy%20in%20Gender%20Affirming%20Care%20for%20Adolescents%20and%20Young%20Adults_%20A%20Retrospective%20Chart%20Review%20(USPATH%202023,%20abstract%20no.%20SUN-B1-T5).pdf">PDF</a>] [<a href="https://files.transfemscience.org/pdfs/wpath-symposia-materials/USPATH%202023%20Symposium%20Abstracts.pdf#page=124">Full Abstract Book</a>]</li>
|
||||
<li>Wilde, B., Diamond, J. B., Laborda, T. J., Frank, L., O’Gorman, M. A., & Kocolas, I. (2023). Bicalutamide-Induced Hepatotoxicity in a Transgender Male-to-Female Adolescent. <em>Journal of Adolescent Health</em>, <em>74</em>(1), 202–204. [DOI:<a href="https://doi.org/10.1016/j.jadohealth.2023.08.024">10.1016/j.jadohealth.2023.08.024</a>]</li>
|
||||
</ul>]]></content><author><name>{"first_name"=>"Aly", "last_name"=>"W.", "author-link"=>"/about/#aly", "articles-link"=>"/articles-by-author/aly/"}</name></author><category term="github" /><category term="workspace" /><summary type="html"><![CDATA[Bicalutamide and its Adoption by the Medical Community for Use in Transfeminine Hormone Therapy By Aly | First published July 1, 2020 | Last modified April 2, 2024]]></summary></entry></feed>
|
||||
</ul>]]></content><author><name>{"first_name"=>"Aly", "last_name"=>"W.", "author-link"=>"/about/#aly", "articles-link"=>"/articles-by-author/aly/"}</name></author><category term="github" /><category term="workspace" /><summary type="html"><![CDATA[Bicalutamide and its Adoption by the Medical Community for Use in Transfeminine Hormone Therapy By Aly | First published July 1, 2020 | Last modified April 6, 2024]]></summary></entry></feed>
|
||||
Reference in New Issue
Block a user